Skip Navigation

JNCI Journal of the National Cancer Institute 2000 92(21):1699; doi:10.1093/jnci/92.21.1699
© 2000 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 92, No. 21, 1699, November 1, 2000
© 2000 Oxford University Press

IN THIS ISSUE

Androgen Suppression for Prostate Cancer

Metastatic prostate cancer is incurable, but hormonal and surgical intervention can relieve its symptoms and may prolong life. However, the costs of different treatment modalities for advanced prostate cancer vary widely. Bayoumi et al. (p. 1731), using decision analysis, computer models, and previously published data, evaluated and compared the cost-effectiveness of six androgen-suppression strategies. They estimated that diethylstilbestrol, the least expensive therapy, was also associated with the lowest quality-adjusted survival. Orchiectomy was the second least expensive but gave the highest estimated quality-adjusted survival of . . . [Full Text of this Article]

Fruit and Vegetables and Colorectal Cancer Incidence

Risk of Esophageal and Gastric Cancers and Selenium

DNA Repair Capacity and Susceptibility to Lung Cancer

Making Beef Patties Safer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?